An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
With
Ono Pharmaceutical Co., Ltd.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with histologically or cytologically confirmed extensive stage disease SCLC
Ongoing response of stable disease or better following 4 cycles of platinum-based first line chemotherapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You may not be if
Subjects with symptomatic Central Nervous System (CNS) metastases
Subjects receiving consolidative chest radiation
Subjects with active, known, or suspected autoimmune disease are excluded
All side effects attributed to prior anti-cancer therapy must have resolved to Grade 1 or baseline
Clareo Health | An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
